ANIK Anika Therapeutics, Inc.
P/E
--
Forward P/E
22.389475
Price/Sales
2.3592727
Beta
0.21
Div Yield
0.0%
Market Cap
--
Company Analysis
Latest News
Anika Therapeutics' third quarter revenue of $31M beat estimates despite missing Commercial Channel targets
Anika Therapeutics reported third quarter 2026 revenue of $30.6 million, exceeding analyst consensus, though the core Commercial Channel underperformed...
Anika Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 06, 2026
Anika Therapeutics is expected to report Q3 2026 consensus revenue of $29.44 million and earnings of $0.42 per share, with the stock currently trading at...